# Rituximab Treatment in Sjogren's Syndrome

> **NCT00363350** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Medical Center Groningen** · enrollment: 30 (estimated)

## Conditions studied

- Sjogren's Syndrome

## Interventions

- **DRUG:** rituximab (anti-CD20)

## Key facts

- **NCT ID:** NCT00363350
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2009-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00363350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00363350, "Rituximab Treatment in Sjogren's Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00363350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*